Cost prediction of antipsychotic medication of psychiatric disorder using artificial neural network model.

作者: Hossein Mirabzadeh , Enayatollah Bakhshi , Akbar Biglarian , Bibi Riahi Mahabadi , Mohamad Reza Khodae

DOI:

关键词:

摘要: BACKGROUND Antipsychotic monotherapy or polypharmacy (concurrent use of two more antipsychotics) are used for treating patients with psychiatric disorders (PDs). Usually, antipsychotic has a lower cost than polypharmacy. This study aimed to predict the medications (AM) in Iran. MATERIALS AND METHODS For this purpose, 790 PDs who were discharged between June and September 2010 selected from Razi Psychiatric Hospital, Tehran, prediction AM PD, neural network (NN) multiple linear regression (MLR) models used. Analysis data was performed R 2.15.1 software. RESULTS Mean ± standard deviation (SD) duration hospitalization (days) on 31.19 15.55 36.69 15.93, respectively (P < 0.001). median costs medication (n = 507) $8.25 $6.23 =192) $13.30 $9.48, The important variables hospitalization, type treatment, ward MLR model, diagnosed disorder, age, Chlorpromazine dosage, disorder NN model. CONCLUSION Our findings showed that artificial (ANN) model can be as flexible AM.

参考文章(29)
Ric M Procyshyn, Nathan B Kennedy, Gordon Tse, Barbara Thompson, Antipsychotic Polypharmacy: A Survey of Discharge Prescriptions from a Tertiary Care Psychiatric Institution The Canadian Journal of Psychiatry. ,vol. 46, pp. 334- 339 ,(2001) , 10.1177/070674370104600404
Paul R. McCrone, Martin Knapp, Anita Patel, Sujith Dhanasiri, Simon Lawton-Smith, Paying the price: the cost of mental health care in England to 2026 The King's Fund. ,(2008)
Christopher M. Bishop, Neural networks for pattern recognition ,(1995)
Chao-Cheng Lin, Ya-Mei Bai, Jen-Yeu Chen, Tzung-Jeng Hwang, Tzu-Ting Chen, Hung-Wen Chiu, Yu-Chuan Li, Easy and Low-Cost Identification of Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotics The Journal of Clinical Psychiatry. ,vol. 71, pp. 225- 234 ,(2010) , 10.4088/JCP.08M04628YEL
Wenyu Ye, Haya Ascher-Svanum, Tanji, Flynn, Takahashi, Robert Conley, Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis. Neuropsychiatric Disease and Treatment. ,vol. 8, pp. 259- 266 ,(2012) , 10.2147/NDT.S25662
Robert Constantine, Rajiv Tandon, Changing trends in pediatric antipsychotic use in Florida's Medicaid program. Psychiatric Services. ,vol. 59, pp. 1162- 1168 ,(2008) , 10.1176/APPI.PS.59.10.1162
Baojin Zhu, Haya Ascher-Svanum, Douglas E Faries, Christoph U Correll, John M Kane, Cost of antipsychotic polypharmacy in the treatment of schizophrenia BMC Psychiatry. ,vol. 8, pp. 19- 19 ,(2008) , 10.1186/1471-244X-8-19
Rahul Ganguly, Jeffrey A. Kotzan, L. Stephen Miller, Klugh Kennedy, Bradley C. Martin, Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. The Journal of Clinical Psychiatry. ,vol. 65, pp. 1377- 1388 ,(2004) , 10.4088/JCP.V65N1013
Xiaomei Peng, Haya Ascher-Svanum, Doug Faries, VL Stauffer, Sara Kollack-Walker, B J Kinon, John Kane, Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy ClinicoEconomics and Outcomes Research. ,vol. 3, pp. 79- 87 ,(2011) , 10.2147/CEOR.S16859